Atazanavir adverse reactions

Revision as of 19:08, 7 January 2014 by Mohamed Moubarak (talk | contribs) (Created page with "__NOTOC__ {{Atazanavir}} {{CMG}}; {{AE}} {{MM}} ==Adverse Reactions== The following adverse reactions are discussed in greater detail in other sections of the labeling: *Car...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Atazanavir
REYATAZ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Adverse Reactions

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Cardiac conduction abnormalities [see Warnings and Precautions ]
  • Rash [see Warnings and Precautions ]
  • Hyperbilirubinemia [see Warnings and Precautions ]
  • Nephrolithiasis and cholelithiasis [see Warnings and Precautions ][1]

References

  1. ↑ "REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Atazanavir_adverse_reactions&oldid=927623"